Fig. 3

Amplification, co-amplification and their prognostic values of LANCL2 and EGFR were verified in GBM samples of tumor banks. A, B Copy numbers of LANCL2 and EGFR in GBM samples of our tumor banks. Normal brain tissues and grade I gliomas were used for comparison. P values were determined by Kruskal–Wallis One-Way ANOVA and Dunn’s multiple comparisons. ***p < 0.001. C Amplification frequencies of LANCL2 and EGFR in GBM samples of tumor banks. D Co-amplification frequencies of LANCL2 and EGFR in total or EGFR-amplified GBM samples. E, F Copy numbers of LANCL2 and EGFR in newly diagnosed and relapsing GBM samples. Normal brain tissues and grade I gliomas were used for comparison. P values were determined by Kruskal–Wallis One-Way ANOVA and Dunn’s multiple comparisons. *p < 0.05; ***p < 0.001. G Pearson’s correlation analysis showed that the copy numbers of LANCL2 and EGFR in GBM were significantly correlated. H Kaplan–Meier survival analysis of LANCL2 or EGFR amplification, and their co-amplification for OS in GBM patients (*p < 0.05). I Forest plot showing the univariate analysis for OS in GBM patients. P values and hazard ratios were determined by log-rank test. J Kaplan–Meier survival analysis of LANCL2 or EGFR amplification, and their co-amplification for OS in younger (< 60 years) GBM patients (*p < 0.05)